Kodiak Sciences (KOD) Cash & Equivalents (2016 - 2026)

Kodiak Sciences has reported Cash & Equivalents for 11 years, with the latest figure at $169.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 22.09% year-over-year to $169.5 million; the trailing twelve-month figure through Mar 2026 stood at $169.5 million (up 22.09% YoY), and the FY2025 full-year result was $209.9 million, up 24.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $169.5 million, down from $209.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $671.7 million in Q1 2022, with the low at $72.0 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $239.5 million across 5 years, with a median of $197.9 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 80.4% — and 2023, when it soared 119.27%.
• Kodiak Sciences' Cash & Equivalents stood at $196.8 million in 2022, then soared by 45.11% to $285.5 million in 2023, then sank by 41.13% to $168.1 million in 2024, then climbed by 24.86% to $209.9 million in 2025, then slipped by 19.22% to $169.5 million in 2026.
• The last three Cash & Equivalents figures came in at $169.5 million (Q1 2026), $209.9 million (Q4 2025), and $72.0 million (Q3 2025), per Business Quant data.